program

AGENDA

Wednesday, October 14, 2009

  • 8:00 a.m. to 8:45 a.m. (Breakfast)
    Registration, Seating
  • 8:45 a.m. to 9 a.m.
    Welcoming remarks, introduction
    - Michelle McMurry-Heath, MD, PhD; Director, The Aspen Health Forum, The Aspen Institute
  • 9 a.m. to 10:15 a.m.
    Strain on the System: Swine Flu and the Public Health Response
    The unfortunate combination of seasonal and swine flu has prompted public health officials to rethink surveillance, containment and vaccine distribution in recent months ― not to mention how to communicate the risks associated with the viruses without spreading panic. As health officials adjust their tactics and urge people to get vaccinated, what new best practices are emerging? And, what can we expect in coming months?

    - Sir Richard Feachem, PhD, DSc; Director, Global Health Group, UCSF
    - Anthony Fauci, MD; Director, National Institute of Allergy and Infectious Diseases, NIH
    - Linda Carnes, DrPA, MPA; Senior Marketing and Communications Officer, CDC (Moderator)
  • 10:15 a.m. to 10:30 a.m.
    Break
  • 10:30 a.m. to 11:45
    The Payoff of Medical Research Reform
    Medical science research holds great promise in the delivery of cures and the prospects for economic recovery. How do we maintain a focus on innovation and risk-taking even as we seek to avoid more expensive health care? Our panelists discuss the potential of biomedical research beyond the act of discovery.

    - David Brennan; CEO, AstraZeneca
    - The Hon. Richard A. Gephardt; President and CEO, Gephardt Government Affairs
    - Jeffrey Kluger; Senior Editor, TIME Magazine (Moderator)
  • 12:00 p.m. to 1:45 p.m. (Lunch)
    Vaccine Wars: Doctors vs. Pathogens
    Emerging diseases such as the recent swine flu underscore the challenges of vaccine production, including how to formulate effective inoculants, produce them in the needed quantities and disseminate them appropriately when supplies are limited. Another heated front in the vaccine wars centers on HPV and the appropriateness of targeted vaccine programs. Our panel weighs in on the challenges and controversies.

    - Gary Nabel, MD, PhD; Director, Vaccine Research Center, NIH
    - George W. Kemble, PhD; Vice President, Research & Development, General Manager, MedImmune
    - Phil Hosbach; Vice President of Immunization Policy and Government Relations, sanofi pasteur
    - Karen A. Goraleski, Vice President, Public Health Partnerships, Research!America (Moderator)

  • 1:45 p.m. to 2:15 p.m.
    A Conversation with The Hon. Billy Tauzin
    America’s pharmaceutical research and biotechnology companies support comprehensive health care reform. The Hon. Billy Tauzin, President and CEO of PhRMA, offers insights on the role that his industry is seeking to play as the nation pursues high-quality and affordable health care coverage and services for all Americans.

    - The Honorable Billy Tauzin, President and CEO, PhRMA
    - Jeffrey Kluger; Senior Editor, TIME Magazine (Host)
  • 2:15 p.m. to 3:30 p.m.
    Personalizing Each Patient
    Comparative effectiveness research is the new holy grail of reducing cost and improving outcomes in health care. But how do we measure the best medicine for most patients while maintaining access to and coverage of rare therapies for rare conditions. Senate Finance Committee Chairman Max Baucus claims that his bill would ensure that government-sponsored research incorporates individual differences among patients. What do you think?

    - Phyllis E. Greenberger, MSW; President and CEO, Society of Women’s Health Research
    - Marc Boutin; Executive Vice President, National Health Council
    - Dan Smith; President, American Cancer Society Cancer Action Network
    - Robert Honigberg, MD, MBA; Former Chief Medical Officer, GE Healthcare
    - Dan Leonard, President and CEO, National Pharmaceutical Council (Moderator)
  • 3:30 p.m. to 5:00 p.m.
    President Obama’s Prospects for Health Reform, Insurance Reform
    What will it take for every American to have access to quality health care? Obama’s strategy for finding out has focused on lowering costs, promoting science and technology research, prioritizing preventative care, and increasingly, on holding insurance companies to greater accountability. As communities of interest make their voices heard and the legislative process unfolds, what elements of the President’s plan are most likely to become law? And, what will they mean for the American people?

    - The Honorable Tom Daschle, Former Senate Majority Leader
    - David B. Snow Jr., Chairman and CEO, Medco
    - Peter Long, Senior Vice President for Executive Operations, Kaiser Family Foundation (Moderator)
  • 5:00 p.m. to 7:30 p.m.
    Reception, in the Top of the Hill Atrium (First Floor).
Register